《20号外显子插入突变与肺癌中的突变：关于从口服激酶抑制剂到抗体药物偶联物的获批靶向治疗的叙述性综述》勘误

Erratum to exon 20 insertion mutations and mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates.

出版信息

Transl Lung Cancer Res. 2024 Oct 31;13(10):2861-2863. doi: 10.21037/tlcr-2024-1. Epub 2024 Oct 12.

DOI:10.21037/tlcr-2024-1

PMID:39507038

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11535847/

Abstract

[This corrects the article DOI: 10.21037/tlcr-23-98.].

摘要

[本文更正了文章的数字对象标识符：10.21037/tlcr-23-98。]

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35af/11535847/4ebef76ee4e2/tlcr-13-10-2861-f2.jpg

相似文献

Erratum to exon 20 insertion mutations and mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates.《20号外显子插入突变与肺癌中的突变：关于从口服激酶抑制剂到抗体药物偶联物的获批靶向治疗的叙述性综述》勘误

Transl Lung Cancer Res. 2024 Oct 31;13(10):2861-2863. doi: 10.21037/tlcr-2024-1. Epub 2024 Oct 12.

exon 20 insertion mutations and mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates.20号外显子插入突变与肺癌：关于从口服激酶抑制剂到抗体药物偶联物等已获批靶向治疗的叙述性综述

Transl Lung Cancer Res. 2023 Jul 31;12(7):1590-1610. doi: 10.21037/tlcr-23-98. Epub 2023 Jul 5.

The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma.EGFR 和 ERBB2 突变型肺腺癌的免疫微环境。

ESMO Open. 2021 Oct;6(5):100253. doi: 10.1016/j.esmoop.2021.100253. Epub 2021 Sep 3.

[Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].[携带表皮生长因子受体第20外显子插入突变的非小细胞肺癌的治疗进展]

Zhongguo Fei Ai Za Zhi. 2022 May 20;25(5):337-350. doi: 10.3779/j.issn.1009-3419.2022.103.01.

Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.针对人类癌症中 EGFR/ErbB 家族蛋白酪氨酸激酶的小分子抑制剂。

Pharmacol Res. 2019 Jan;139:395-411. doi: 10.1016/j.phrs.2018.11.014. Epub 2018 Nov 27.

Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review.针对携带表皮生长因子受体（EGFR）第20外显子插入突变的非小细胞肺癌的新兴疗法：叙述性综述

Ann Transl Med. 2022 Dec;10(23):1283. doi: 10.21037/atm-2022-56.

and exon 20 insertion/duplication in advanced non-small cell lung cancer: genomic profiling and clinicopathologic features.晚期非小细胞肺癌中第20外显子插入/重复：基因组分析与临床病理特征

Front Oncol. 2023 May 22;13:1163485. doi: 10.3389/fonc.2023.1163485. eCollection 2023.

EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors.EGFR 外显子 19 插入 EGFR-K745_E746insIPVAIK 和其他罕见的 XPVAIK 氨基酸插入：所有批准的 EGFR 激酶抑制剂的有利治疗窗口的临床前和临床特征。

Lung Cancer. 2023 Jul;181:107250. doi: 10.1016/j.lungcan.2023.107250. Epub 2023 May 13.

Advances in the management of non-small-cell lung cancer harbouring exon 20 insertion mutations.携带20号外显子插入突变的非小细胞肺癌的治疗进展

Ther Adv Med Oncol. 2023 Jan 27;15:17588359221146131. doi: 10.1177/17588359221146131. eCollection 2023.

Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion.免疫检查点抑制剂联合化疗在 EGFR/ERBB2 外显子 20 插入的肺癌患者中疗效不佳。

Curr Oncol. 2023 Nov 14;30(11):9929-9939. doi: 10.3390/curroncol30110721.

本文引用的文献

Transl Lung Cancer Res. 2023 Jul 31;12(7):1590-1610. doi: 10.21037/tlcr-23-98. Epub 2023 Jul 5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

《20号外显子插入突变与肺癌中的突变：关于从口服激酶抑制剂到抗体药物偶联物的获批靶向治疗的叙述性综述》勘误

Erratum to exon 20 insertion mutations and mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates.

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献